オプションチェーンは、Tevogen Bio Holdingsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Tevogen Bio Holdingsの市場センチメントを評価します。.

Tevogen Bio Holdings (NASDAQ:TVGN) 株価情報, オプションチェーン

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Tevogen Bio Holdings Inc

WIIM

Pfizer shares are trading higher following a Q1 EPS beat. The company reaffirmed guidance but said it is trending towards the upper end of its 2025 Adjusted diluted EPS guidance range.

News

General

FFIN

First Financial Increases Its Dividend To $0.19

Novo Nordisk shares are trading higher after the company announced Wegovy partnerships with Hims and LifeMD.

<h3>Gainers</h3>
<ul>
<li><strong>Travelzoo</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZOO#NASDAQ">TZOO</a>) shares moved upwards by 20.8% to $15.13 during Tuesday's regular session. The market value of their outstanding shares is at $170.1 million. As per the press release, Q1 earnings came out today. </li>
<li><strong>36KR Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRKR#NASDAQ">KRKR</a>) stock increased by 16.3% to $5.0. The company's market cap stands at $9.8 million. </li>
<li><strong>LZ Technology Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZMH#NASDAQ">LZMH</a>) stock rose 13.73% to $9.11. The market value of their outstanding shares is at $1.3 billion. </li>
<li><strong>LiveOne</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVO#NASDAQ">LVO</a>) shares rose 13.44% to $0.74. The market value of their outstanding shares is at $71.4 million. </li>
<li><strong>Phoenix New Media</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FENG#NYSE">FENG</a>) stock rose 11.7% to $2.1. The company's market cap stands at $25.2 million. </li>
<li><strong>EPWK Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPWK#NASDAQ">EPWK</a>) shares moved upwards by 11.53% to $15.29. The company's market cap stands at $341.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>iOThree</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOTR#NASDAQ">IOTR</a>) shares declined by 27.5% to $0.66 during Tuesday's regular session. The company's market cap stands at $16.9 million. </li>
<li><strong>Intelligent Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTJ#NASDAQ">INTJ</a>) shares fell 15.44% to $0.57. The market value of their outstanding shares is at $7.4 million. </li>
<li><strong>Surgepays</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>) shares declined by 11.01% to $2.91. The market value of their outstanding shares is at $59.3 million. </li>
<li><strong>Beasley Broadcast Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>) stock decreased by 10.1% to $5.58. The market value of their outstanding shares is at $9.8 million. </li>
<li><strong>Haoxi Health Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAO#NASDAQ">HAO</a>) stock fell 9.63% to $1.31. The market value of their outstanding shares is at $3.6 million. </li>
<li><strong>Motorsport Games</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) stock decreased by 9.4% to $2.4. The company's market cap stands at $12.1 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

BBGI

EPWK

FENG

INTJ

IOTR

KRKR

LZMH

MSGM

SURG

TZOO

12 Communication Services Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li><strong>LogicMark</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares rose 50.4% to $0.02 during Tuesday's regular session. </li>
<li><strong>Kala Bio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) stock rose 39.13% to $4.97. The market value of their outstanding shares is at $30.2 million. </li>
<li><strong>ENDRA Life Sciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares increased by 33.48% to $5.74. The market value of their outstanding shares is at $3.0 million. </li>
<li><strong>LifeMD</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) shares moved upwards by 32.78% to $8.1. The market value of their outstanding shares is at $361.1 million. </li>
<li><strong>iBio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares increased by 27.14% to $1.33. The market value of their outstanding shares is at $13.1 million. </li>
<li><strong>Hims &amp; Hers Health</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) stock rose 26.12% to $35.92. The company's market cap stands at $8.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Petros Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock decreased by 71.0% to $0.02 during Tuesday's regular session. </li>
<li><strong>Zhengye Biotechnology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares decreased by 34.63% to $9.25. The company's market cap stands at $438.3 million. </li>
<li><strong>NeoGenomics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) stock declined by 31.9% to $6.79. The market value of their outstanding shares is at $872.2 million. The company's, Q1 earnings came out today. </li>
<li><strong>Tivic Health Systems</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock decreased by 25.2% to $4.84. The company's market cap stands at $2.9 million. </li>
<li><strong>Universe Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock declined by 23.37% to $4.56. The company's market cap stands at $69.4 million. </li>
<li><strong>Relmada Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) stock fell 15.99% to $0.3. The company's market cap stands at $9.9 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hims & Hers Health, Inc. Class A Common Stock

HIMS

IBIO

KALA

LFMD

LGMK

NDRA

PTPI

RLMD

TIVC

ZYBT

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li><strong>Clarivate</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLVT#NYSE">CLVT</a>) shares moved upwards by 16.6% to $4.18 during Tuesday's regular session. The company's market cap stands at $2.8 billion. The company's, Q1 earnings came out today. </li>
<li><strong>Primech Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>) stock increased by 16.33% to $0.99. The company's market cap stands at $37.7 million. </li>
<li><strong>CECO Environmental</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) stock increased by 16.3% to $22.33. The market value of their outstanding shares is at $781.3 million. As per the news, the Q1 earnings report came out today. </li>
<li><strong>LanzaTech Global</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) shares increased by 16.14% to $0.24. The market value of their outstanding shares is at $47.8 million. </li>
<li><strong>Odyssey Marine Explr</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) stock moved upwards by 15.15% to $1.52. The market value of their outstanding shares is at $44.3 million. </li>
<li><strong>Greenland Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTEC#NASDAQ">GTEC</a>) stock moved upwards by 14.55% to $1.81. The market value of their outstanding shares is at $24.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Marwynn Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MWYN#NASDAQ">MWYN</a>) shares declined by 28.0% to $2.93 during Tuesday's regular session. The company's market cap stands at $49.9 million. </li>
<li><strong>Kforce</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFRC#NYSE">KFRC</a>) shares declined by 15.81% to $36.0. The company's market cap stands at $687.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li><strong>Amprius Technologies</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) stock fell 15.77% to $2.14. The market value of their outstanding shares is at $257.9 million. </li>
<li><strong>Insperity</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>) shares declined by 15.22% to $66.65. The market value of their outstanding shares is at $2.5 billion. As per the news, the Q1 earnings report came out today. </li>
<li><strong>AgEagle Aerial Sys</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#AMEX">UAVS</a>) shares declined by 15.05% to $0.96. The company's market cap stands at $12.3 million. </li>
<li><strong>Northann</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) stock fell 14.78% to $0.36. The market value of their outstanding shares is at $19.9 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AMPX

CECO

CLVT

GTEC

KFRC

LNZA

MWYN

Nuveen Insured California Premium Fund Ii

OMEX

PMEC

UAVS

12 Industrials Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li><strong>Saiheat</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIH#NASDAQ">SAIH</a>) shares increased by 21.8% to $9.1 during Tuesday's regular session. The market value of their outstanding shares is at $15.4 million. As per the press release, FY earnings came out yesterday. </li>
<li><strong>Nvni Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) shares moved upwards by 17.36% to $0.18. The market value of their outstanding shares is at $16.7 million. </li>
<li><strong>Vishay Precision Group</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VPG#NYSE">VPG</a>) stock increased by 14.88% to $25.4. The market value of their outstanding shares is at $336.7 million. </li>
<li><strong>Sigmatron Intl</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMA#NASDAQ">SGMA</a>) stock moved upwards by 14.17% to $1.36. The market value of their outstanding shares is at $8.3 million. </li>
<li><strong>Locafy</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) stock moved upwards by 13.09% to $5.7. The company's market cap stands at $7.2 million. </li>
<li><strong>Focus Universal</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) shares moved upwards by 12.68% to $5.42. The market value of their outstanding shares is at $40.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Daqo New Energy</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) shares fell 16.1% to $12.42 during Tuesday's regular session. The market value of their outstanding shares is at $816.7 million. The company's, Q1 earnings came out today. </li>
<li><strong>Wolfspeed</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares fell 16.11% to $3.46. The company's market cap stands at $539.0 million. </li>
<li><strong>Ultra Clean Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) stock fell 13.61% to $19.27. The market value of their outstanding shares is at $869.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li><strong>ACM Research</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) shares declined by 12.84% to $18.13. The market value of their outstanding shares is at $1.1 billion. </li>
<li><strong>Mercurity Fintech Holding</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) shares declined by 11.88% to $6.83. The market value of their outstanding shares is at $434.8 million. </li>
<li><strong>Pony AI</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) stock decreased by 11.63% to $9.12. The market value of their outstanding shares is at $3.1 billion.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ACMR

FCUV

LCFY

NVNI

PONY

SAIH

SGMA

UCTT

WOLF

12 Information Technology Stocks Moving In Tuesday's Intraday Session

<p>Historically, markets deliver weaker and more volatile returns during the May through October timeframe than any other time of the year. Hence, the old adage: "Sell in May and go away." Negative May through October returns, though, typically show up<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/04/45069781/trumps-first-100-days-what-he-delivered-where-he-fell-short-how-markets-reacted"> only in bear markets.&nbsp;</a></p>
<p><strong>What To Know: Callum Thomas</strong>, head of research for Top Down Charts, claims that the old adage "Sell in May and go away" oversimplifies reality. While the May-October stretch often underperforms, seasonality behaves differently in bull versus bear markets.&nbsp;</p>
<p><strong>Read Next: </strong><a href="https://www.benzinga.com/news/legal/25/04/45056354/alexandria-ocasio-cortez-askshow-much-did-majorie-taylor-greene-make-when-she-bought-the-dip?utm_source=articleShare"><strong>Alexandria Ocasio-Cortez Asks,&#8217;How Much Did Majorie Taylor Greene Make When She Bought The Dip?&#8217;</strong></a></p>
<p>Thomas says the "Sell in May" effect is most pronounced during bear markets, but bull markets still see gains, just with more bumps.</p>
<p>In bull markets, May through October still produces positive returns less often than November through April. In bear markets, the odds of losses spike during the May through October window.</p>
<p>This year, the S&amp;P 500, as tracked by the <strong>SPDR S&amp;P 500 ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), is down 5.61% heading into May. </p>
<p><strong>Why Does This Happen: </strong>Economic data and investor sentiment tend to be weaker from May to October, which Thomas says may help explain the seasonal dip.&nbsp;</p>
<p>The U.S. dollar often weakens, while oil prices tend to rise during this period. Defensive assets, like treasuries and gold, often outperform during the May through October stretch, reflecting the risk-off mood.</p>
<p><strong>What Else:</strong> Averages can be misleading, Thomas warns, and the performance gap between the two periods has been shrinking in recent years. Seasonality should be considered as part of a strategy, but not as a stand-alone investment thesis.&nbsp;</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><a href="https://www.benzinga.com/25/04/45012792/trump-administration-to-resume-collections-on-student-loans-5-million-borrowers-in-default?utm_source=articleShare"><strong>Trump Administration To Resume Collections On Student Loans: 5 Million Borrowers In Default&nbsp;</strong></a></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Equities

Social Media

Broad U.S. Equity ETFs

Markets

ETFs

'Sell In May And Go Away?' Only In Bear Markets, One Expert Says

KEYS

Keysight Technologies Collaborates With Intel Foundry To Support Embedded Multi-Die Interconnect Bridge-T Technology

<p><strong>Gibraltar Industries</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROCK#NASDAQ">ROCK</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Gibraltar Industries will report an <strong>earnings per share</strong> (EPS) of $0.81. </p>
<p>Investors in Gibraltar Industries are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company beat EPS by $0.10, leading to a 0.74% increase in the share price the following trading session.</p>
<p>Here's a look at Gibraltar Industries's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.91</td>
<td>1.25</td>
<td>1.25</td>
<td>0.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.27</td>
<td>1.18</td>
<td>0.80</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745946221_0.png" alt="eps graph" /></p>
<h3>Tracking Gibraltar Industries's Stock Performance</h3>
<p>Shares of Gibraltar Industries were trading at $52.59 as of April 28. Over the last 52-week period, shares are up 486.51%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ROCK/earnings"><strong>To track all earnings releases for Gibraltar Industries visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

ROCK

Earnings Preview: Gibraltar Industries

<p>Climb Global Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMB#NASDAQ">CLMB</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Climb Global Solutions to report an <strong>earnings per share</strong> (EPS) of $0.89.</p>
<p>The market awaits Climb Global Solutions's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $1.14 in the last quarter, leading to a 12.78% increase in the share price on the following day.</p>
<p>Here's a look at Climb Global Solutions's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.12</td>
<td>0.85</td>
<td>0.48</td>
<td>0.75</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.26</td>
<td>1.55</td>
<td>0.83</td>
<td>0.60</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>13.0%</td>
<td>-3.0%</td>
<td>13.0%</td>
<td>-11.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745946206_0.png" alt="eps graph" /></p>
<h3>Tracking Climb Global Solutions's Stock Performance</h3>
<p>Shares of Climb Global Solutions were trading at $107.28 as of April 28. Over the last 52-week period, shares are up 61.86%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Take on Climb Global Solutions</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Climb Global Solutions.</p>
<p>Analysts have given Climb Global Solutions a total of 2 ratings, with the consensus rating being Outperform. The average one-year price target is $136.0, indicating a potential 26.77% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Ingram Micro Holding, Insight Enterprises and Avnet, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Ingram Micro Holding, with an average 1-year price target of $25.8, suggesting a potential 75.95% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Insight Enterprises, with an average 1-year price target of $160.0, suggesting a potential 49.14% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Avnet, with an average 1-year price target of $50.0, suggesting a potential 53.39% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>In the peer analysis summary, key metrics for Ingram Micro Holding, Insight Enterprises and Avnet are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Climb Global Solutions</td>
<td>Outperform</td>
<td>51.48%</td>
<td>$31.25M</td>
<td>7.65%</td>
</tr>
<tr>
<td>Ingram Micro Holding</td>
<td>Buy</td>
<td>2.50%</td>
<td>$936.09M</td>
<td>2.26%</td>
</tr>
<tr>
<td>Insight Enterprises</td>
<td>Neutral</td>
<td>-7.31%</td>
<td>$439.64M</td>
<td>2.09%</td>
</tr>
<tr>
<td>Avnet</td>
<td>Neutral</td>
<td>-8.73%</td>
<td>$596.05M</td>
<td>1.77%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Climb Global Solutions ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity. Overall, Climb Global Solutions stands out for its strong revenue growth and gross profit performance compared to its peers, despite a lower return on equity.</p>
<h3>Unveiling the Story Behind Climb Global Solutions</h3>
<p>Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.</p>
<h3>Breaking Down Climb Global Solutions's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Climb Global Solutions's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>51.48%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Climb Global Solutions's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.21%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Climb Global Solutions's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.65%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.62%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.03</strong>, Climb Global Solutions adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/CLMB/earnings"><strong>To track all earnings releases for Climb Global Solutions visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CLMB

Insights into Climb Global Solutions's Upcoming Earnings

<p>PC Connection (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXN#NASDAQ">CNXN</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate PC Connection to report an <strong>earnings per share</strong> (EPS) of $0.41.</p>
<p>The market awaits PC Connection's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.12, leading to a 10.81% drop in the share price on the subsequent day.</p>
<p>Here's a look at PC Connection's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.90</td>
<td>1</td>
<td>0.83</td>
<td>0.63</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.78</td>
<td>0.97</td>
<td>1</td>
<td>0.50</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-11.0%</td>
<td>-5.0%</td>
<td>5.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745946198_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of PC Connection were trading at $61.97 as of April 28. Over the last 52-week period, shares are up 0.24%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CNXN/earnings"><strong>To track all earnings releases for PC Connection visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CNXN

A Preview Of PC Connection's Earnings

<p><strong>MYR Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYRG#NASDAQ">MYRG</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that MYR Group will report an <strong>earnings per share</strong> (EPS) of $1.17. </p>
<p>MYR Group bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.31, leading to a 4.67% drop in the share price on the subsequent day.</p>
<p>Here's a look at MYR Group's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.68</td>
<td>0.35</td>
<td>1.13</td>
<td>1.16</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.99</td>
<td>0.65</td>
<td>-0.91</td>
<td>1.12</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>14.000000000000002%</td>
<td>-22.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745946191_0.png" alt="eps graph" /></p>
<h3>Performance of MYR Group Shares</h3>
<p>Shares of MYR Group were trading at $122.95 as of April 28. Over the last 52-week period, shares are down 25.22%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MYRG/earnings"><strong>To track all earnings releases for MYR Group visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MYRG

Uncovering Potential: MYR Group's Earnings Preview

<p>U.S. Secretary of Commerce <strong>Howard Lutnick</strong> has outlined a bold vision to position the United States as the global leader in <strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) innovation, <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45017261/bitcoin-mining-costs-jump-to-137000-per-coin-when-accounting-for-non-cash-expenses-coinshares">starting with mining</a>.</p>
<p><strong>What Happened:</strong> In a Bitcoin Magazine exclusive interview on April 28, Lutnick <a href="https://www.youtube.com/watch?v=BPlnUxDblaE">proposed</a> a revolutionary approach: allowing Bitcoin miners to build power plants directly at mining sites, including the ability to place data centers &#8220;on top of gas fields&#8221; with dedicated energy sources.</p>
<p>This would eliminate reliance on the broader electrical grid and enable miners to scale sustainably.</p>
<p>&#8220;If you want to mine Bitcoin and find the right place to do it, you can build your own power plant next to it,&#8221; Lutnick said.</p>
<p>This strategy falls under the Investment Accelerator program, which offers regulatory support for large-scale investments in U.S. infrastructure: investments over $1 billion get streamlined permitting assistance. </p>
<p>Projects over $10 billion receive dedicated full-time government liaisons offering &#8220;white glove service.&#8221;</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45048427/watch-this-bitcoin-indicator-to-know-if-a-run-to-100000-is-coming">Watch This Bitcoin Indicator To Know If A Run To $100,000 Is Coming</a></strong></p>
<p><strong>Why It Matters:</strong> Lutnick, who began investing in Bitcoin in 2017 and went &#8220;all in&#8221; by 2020, emphasized that this administration is crypto-forward. </p>
<p>There are three major Bitcoin advocates in key positions: President Trump, &#8216;Crypto Czar&#8217; <strong>David Sacks</strong>, and myself, he said.</p>
<p>He likened Bitcoin to gold, arguing it should be treated as a commodity, not a security: "What is Bitcoin like? It's like gold… You should be able to buy and sell Bitcoin freely—it's a commodity." </p>
<p>Lutnick also revealed discussions within the Bureau of Economic Analysis to treat Bitcoin similarly to gold bullion in national economic data, a move that could elevate its standing in financial reporting.</p>
<p><strong>What's Next: </strong>While Lutnick declined to update the status of a proposed Bitcoin strategic reserve audit, he reaffirmed that the administration has delivered on key promises to the crypto industry.</p>
<p>He noted that further Bitcoin-focused policies will resume after the administration addresses global trade and geopolitical stability.</p>
<p>Lutnick contrasted the current approach with the prior administration, saying: "was treated under the Biden administration like you were doing something wrong&#8230;now you have that sort of in the rearview mirror and then it&#8217;s gone and it&#8217;ll never come back.&#8221;</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://in.benzinga.com/markets/cryptocurrency/25/04/45036669/bitcoin-supply-squeeze-will-drive-run-to-new-highs-bernstein">Bitcoin Supply Squeeze Will Drive Run To New Highs: Bernstein</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Is A Commodity Like Gold, Says Commerce Secretary Lutnick

<p>Cimpress (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPR#NASDAQ">CMPR</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-30. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Cimpress to report an <strong>earnings per share</strong> (EPS) of $0.55.</p>
<p>Investors in Cimpress are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.07, leading to a 5.48% drop in the share price the following trading session.</p>
<p>Here's a look at Cimpress's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.43</td>
<td>0.29</td>
<td>0.95</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.36</td>
<td>-0.50</td>
<td>4.33</td>
<td>-0.15</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>-9.0%</td>
<td>5.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745946183_0.png" alt="eps graph" /></p>
<h3>Market Performance of Cimpress's Stock</h3>
<p>Shares of Cimpress were trading at $41.97 as of April 28. Over the last 52-week period, shares are down 49.62%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CMPR/earnings"><strong>To track all earnings releases for Cimpress visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CMPR

What to Expect from Cimpress's Earnings

<p><strong>Tandem Diabetes Care</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Tandem Diabetes Care will report an <strong>earnings per share</strong> (EPS) of $-0.42. </p>
<p>Investors in Tandem Diabetes Care are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS missed by $0.20 in the last quarter, leading to a 35.25% drop in the share price on the following day.</p>
<p>Here's a look at Tandem Diabetes Care's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.24</td>
<td>-0.40</td>
<td>-0.54</td>
<td>-0.76</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.44</td>
<td>-0.36</td>
<td>-0.48</td>
<td>-0.64</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-35.0%</td>
<td>-3.0%</td>
<td>18.0%</td>
<td>22.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745946176_0.png" alt="eps graph" /></p>
<h3>Tracking Tandem Diabetes Care's Stock Performance</h3>
<p>Shares of Tandem Diabetes Care were trading at $17.47 as of April 28. Over the last 52-week period, shares are down 52.47%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analysts' Perspectives on Tandem Diabetes Care</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Tandem Diabetes Care.</p>
<p>Tandem Diabetes Care has received a total of 9 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $35.11, the consensus suggests a potential 100.97% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Integra Lifesciences, Artivion and Omnicell, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Integra Lifesciences, with an average 1-year price target of $27.0, suggesting a potential 54.55% upside.</li>
<li>Analysts currently favor an Buy trajectory for Artivion, with an average 1-year price target of $31.67, suggesting a potential 81.28% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Omnicell, with an average 1-year price target of $45.33, suggesting a potential 159.47% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Integra Lifesciences, Artivion and Omnicell, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tandem Diabetes Care</td>
<td>Neutral</td>
<td>43.62%</td>
<td>$157.46M</td>
<td>0.30%</td>
</tr>
<tr>
<td>Integra Lifesciences</td>
<td>Neutral</td>
<td>11.49%</td>
<td>$249.07M</td>
<td>1.27%</td>
</tr>
<tr>
<td>Artivion</td>
<td>Buy</td>
<td>3.88%</td>
<td>$61.50M</td>
<td>-5.66%</td>
</tr>
<tr>
<td>Omnicell</td>
<td>Neutral</td>
<td>18.56%</td>
<td>$141.76M</td>
<td>1.28%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Tandem Diabetes Care ranks highest in Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, Tandem Diabetes Care is at the bottom compared to its peers.</p>
<h3>Get to Know Tandem Diabetes Care Better</h3>
<p>Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.</p>
<h3>Key Indicators: Tandem Diabetes Care's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Tandem Diabetes Care displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>43.62%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Tandem Diabetes Care's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>0.27%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Tandem Diabetes Care's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>0.3%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Tandem Diabetes Care's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.08%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Tandem Diabetes Care's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.8</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<p><a href="https://www.benzinga.com/quote/TNDM/earnings"><strong>To track all earnings releases for Tandem Diabetes Care visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TNDM

Insights into Tandem Diabetes Care's Upcoming Earnings

<p><strong>MGIC Investment</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTG#NYSE">MTG</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that MGIC Investment will report an <strong>earnings per share</strong> (EPS) of $0.69. </p>
<p>Investors in MGIC Investment are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.06, leading to a 1.79% increase in the share price on the subsequent day.</p>
<p>Here's a look at MGIC Investment's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.66</td>
<td>0.66</td>
<td>0.63</td>
<td>0.60</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.72</td>
<td>0.77</td>
<td>0.77</td>
<td>0.65</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745946168_0.png" alt="eps graph" /></p>
<h3>Performance of MGIC Investment Shares</h3>
<p>Shares of MGIC Investment were trading at $24.56 as of April 28. Over the last 52-week period, shares are up 19.51%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Insights Shared by Analysts on MGIC Investment</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding MGIC Investment.</p>
<p>The consensus rating for MGIC Investment is Neutral, based on 4 analyst ratings. With an average one-year price target of $26.25, there's a potential 6.88% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Mr. Cooper Gr and Walker &amp; Dunlop, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Mr. Cooper Gr, with an average 1-year price target of $134.12, suggesting a potential 446.09% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Walker &amp; Dunlop, with an average 1-year price target of $101.67, suggesting a potential 313.97% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Mr. Cooper Gr and Walker &amp; Dunlop, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>PennyMac Financial Servs</td>
<td>Outperform</td>
<td>53.22%</td>
<td>$281.12M</td>
<td>1.97%</td>
</tr>
<tr>
<td>Mr. Cooper Gr</td>
<td>Neutral</td>
<td>3.74%</td>
<td>$343M</td>
<td>1.81%</td>
</tr>
<tr>
<td>Walker &amp; Dunlop</td>
<td>Outperform</td>
<td>24.46%</td>
<td>$156.35M</td>
<td>2.45%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>MGIC Investment ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit and Return on Equity.</p>
<h3>Discovering MGIC Investment: A Closer Look</h3>
<p>MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection accounts for close to majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia and New York.</p>
<h3>Unraveling the Financial Story of MGIC Investment</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining MGIC Investment's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>6.16%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> MGIC Investment's net margin is impressive, surpassing industry averages. With a net margin of <strong>61.27%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> MGIC Investment's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>3.53%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> MGIC Investment's ROA excels beyond industry benchmarks, reaching <strong>2.79%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.12</strong>, MGIC Investment adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/MTG/earnings"><strong>To track all earnings releases for MGIC Investment visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Preview: MGIC Investment's Earnings

<p>Magnolia Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-30. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Magnolia Oil &amp; Gas will report an <strong>earnings per share</strong> (EPS) of $0.53.</p>
<p>Anticipation surrounds Magnolia Oil &amp; Gas's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.04, leading to a 1.51% increase in the share price the following trading session.</p>
<p>Here's a look at Magnolia Oil &amp; Gas's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.45</td>
<td>0.48</td>
<td>0.54</td>
<td>0.46</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.49</td>
<td>0.53</td>
<td>0.52</td>
<td>0.49</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-1.0%</td>
<td>-6.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745946158_0.png" alt="eps graph" /></p>
<h3>Performance of Magnolia Oil &amp; Gas Shares</h3>
<p>Shares of Magnolia Oil &amp; Gas were trading at $21.67 as of April 28. Over the last 52-week period, shares are down 13.16%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analysts' Perspectives on Magnolia Oil &amp; Gas</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Magnolia Oil &amp; Gas.</p>
<p>A total of 7 analyst ratings have been received for Magnolia Oil &amp; Gas, with the consensus rating being Neutral. The average one-year price target stands at $25.14, suggesting a potential 16.01% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of CNX Resources, California Resources and Gulfport Energy, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Underperform trajectory for CNX Resources, with an average 1-year price target of $31.56, suggesting a potential 45.64% upside.</li>
<li>Analysts currently favor an Neutral trajectory for California Resources, with an average 1-year price target of $52.67, suggesting a potential 143.05% upside.</li>
<li>Analysts currently favor an Buy trajectory for Gulfport Energy, with an average 1-year price target of $216.67, suggesting a potential 899.86% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for CNX Resources, California Resources and Gulfport Energy, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnolia Oil &amp; Gas</td>
<td>Neutral</td>
<td>1.23%</td>
<td>$163.18M</td>
<td>4.43%</td>
</tr>
<tr>
<td>CNX Resources</td>
<td>Underperform</td>
<td>61.95%</td>
<td>$345.57M</td>
<td>-5.03%</td>
</tr>
<tr>
<td>California Resources</td>
<td>Neutral</td>
<td>55.03%</td>
<td>$1.34B</td>
<td>0.94%</td>
</tr>
<tr>
<td>Gulfport Energy</td>
<td>Buy</td>
<td>8.28%</td>
<td>$181.24M</td>
<td>-14.49%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>In terms of consensus, Magnolia Oil &amp; Gas is rated neutral, placing it in the middle compared to its peers. It ranks second in revenue growth among the group. The company's gross profit is the second lowest. However, Magnolia Oil &amp; Gas has the highest return on equity among its peers.</p>
<h3>Get to Know Magnolia Oil &amp; Gas Better</h3>
<p>Magnolia Oil &amp; Gas Corp is an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquid (NGL) reserves. The company's oil and natural gas properties are located in Karnes County and the Giddings area in South Texas, where the Company targets the Eagle Ford Shale and Austin Chalk formations. Its objective is to generate stock market value over the long term through consistent organic production growth, high full-cycle operating margins, and an efficient capital program with short economic paybacks. The company's operating segment is acquisition, development, exploration, and production of oil and natural gas properties located in the United States.</p>
<h3>Magnolia Oil &amp; Gas's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Magnolia Oil &amp; Gas displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>1.23%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> Magnolia Oil &amp; Gas's net margin is impressive, surpassing industry averages. With a net margin of <strong>25.91%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.43%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Magnolia Oil &amp; Gas's ROA excels beyond industry benchmarks, reaching <strong>3.01%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.21</strong>.</p>
<p><a href="https://www.benzinga.com/quote/MGY/earnings"><strong>To track all earnings releases for Magnolia Oil &amp; Gas visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into Magnolia Oil & Gas's Upcoming Earnings

<p><strong>MGM Resorts Intl</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that MGM Resorts Intl will report an <strong>earnings per share</strong> (EPS) of $0.46. </p>
<p>The market awaits MGM Resorts Intl's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.11, leading to a 17.46% increase in the share price the following trading session.</p>
<p>Here's a look at MGM Resorts Intl's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.34</td>
<td>0.61</td>
<td>0.62</td>
<td>0.56</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.45</td>
<td>0.54</td>
<td>0.86</td>
<td>0.74</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>17.0%</td>
<td>-11.0%</td>
<td>-13.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745946149_0.png" alt="eps graph" /></p>
<h3>Performance of MGM Resorts Intl Shares</h3>
<p>Shares of MGM Resorts Intl were trading at $32.21 as of April 28. Over the last 52-week period, shares are down 20.75%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analysts' Take on MGM Resorts Intl</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on MGM Resorts Intl.</p>
<p>Analysts have provided MGM Resorts Intl with 12 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $46.75, suggesting a potential 45.14% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Light &amp; Wonder, Churchill Downs and Caesars Entertainment, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Light &amp; Wonder, with an average 1-year price target of $107.2, suggesting a potential 232.82% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Churchill Downs, with an average 1-year price target of $144.93, suggesting a potential 349.95% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Caesars Entertainment, with an average 1-year price target of $42.58, suggesting a potential 32.19% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary outlines pivotal metrics for Light &amp; Wonder, Churchill Downs and Caesars Entertainment, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MGM Resorts International</td>
<td>Outperform</td>
<td>-0.66%</td>
<td>$1.95B</td>
<td>4.94%</td>
</tr>
<tr>
<td>Light &amp; Wonder</td>
<td>Buy</td>
<td>3.37%</td>
<td>$566M</td>
<td>14.46%</td>
</tr>
<tr>
<td>Churchill Downs</td>
<td>Outperform</td>
<td>8.75%</td>
<td>$189.50M</td>
<td>7.12%</td>
</tr>
<tr>
<td>Caesars Entertainment</td>
<td>Outperform</td>
<td>-0.92%</td>
<td>$1.40B</td>
<td>0.26%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>MGM Resorts Intl ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit and Return on Equity.</p>
<h3>Discovering MGM Resorts Intl: A Closer Look</h3>
<p>MGM Resorts is the largest resort operator on the Las Vegas Strip with 37,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Park MGM, Luxor, New York-New York, and Bellagio. The Strip contributed approximately 59% of total EBITDAR in 2024. MGM also owns US regional assets, which represented a low 20s share of 2024 EBITDAR (MGM's Macao EBITDAR was 21% of the total in 2024). MGM's US sports and i-gaming operations are currently a high-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM China casinos with a new property that opened on the Cotai Strip in early 2018. We estimate MGM will open a resort in Japan in 2030.</p>
<h3>Financial Insights: MGM Resorts Intl</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining MGM Resorts Intl's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-0.66%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> MGM Resorts Intl's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>3.55%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.94%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> MGM Resorts Intl's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.36%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> MGM Resorts Intl's debt-to-equity ratio is below the industry average at <strong>10.45</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/MGM/earnings"><strong>To track all earnings releases for MGM Resorts Intl visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MGM Resorts Intl's Earnings Outlook

Analyst Ratings

Trading Ideas

ABBV

iShares Trust Dow Jones US Industrial Sector Index Fund

NFLX

CNBC Halftime Report Final Trades: Netflix, AbbVie, iShares U.S. Industrials, Sherwin-Williams Company

Press Releases

Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission

Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs

Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Contracts

Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

Small Cap

WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market

Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility

Tevogen Bio Announces 2025 Annual Meeting

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

AMST

AVAI

BTAI

PLTR

TVGN

TVGNW

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Fate Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Genfit

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Inhibrx Biosciences

INmune Bio

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Korro Bio

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nanobiotix

Nkarta

Puma Biotechnology

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tango Therapeutics

Y-mAbs Therapeutics

D. Boral Capital

Tevogen Bio Holdings shares are trading higher after the company reaffirmed its oncology pipeline revenue forecast, projecting $1 billion in its launch year and a cumulative five-year estimate of $10 billion to $14 billion.

Comments

Tevogen Bio Holdings

Tevogen Bio Holdings (TVGN) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル